Merus and Selexis will combine technology platforms to produce colorectal cancer combination therapy.
Merus, which develops bispecific antibody therapeutics to treat cancer patients, and Selexis, which has technologies for biologics drug discovery and Research Cell Bank (RCB) development, received a EUREKA Eurostars grant of €2.1 million (USD 2.33 million) to develop bispecific antibody combination products for the treatment of colorectal cancer, the companies announced on May 20, 2015.
In the program, Merus and Selexis will combine their unique and proprietary Oligoclonics and SUREtechnology platforms, respectively, to develop a product combining two, bispecific, full-length immunoglobulin G antibodies that simultaneously targets and potently inhibits three receptor tyrosine kinases. The lead Oligoclonics candidate was discovered as part of a previous EUREKA program and will be produced from a single manufacturing cell line developed by Selexis.
“Combining drugs is at the heart of therapeutic approaches to cancer,” said Mark Throsby, CSO of Merus, in a press release. “Bispecific antibody combinations have potency and targeting advantages that provide the basis for improved anti-cancer therapies. With the best-in-class RCB generation capabilities of Selexis on board, the existing knowledge and infrastructure for the manufacturing of therapeutic monoclonal antibodies is optimally leveraged. This collaboration represents an important step towards affordable combination therapies for cancer.”
“The unique SUREtechnology Platform based on a proprietary cell line will deliver an unprecedented timeline from transfection to RCB in just 12 weeks,” said Dr. Igor Fisch, CEO of Selexis, in a press release. “With our optimized off-the-shelf CHO media and feeds, we will maximize expression of the bispecific antibody combinations generated from Merus’ Oligoclonics platform. This will save the project substantial cost and time and facilitate a more rapid delivery of innovative therapeutics to cancer patients”
Source: Selexis
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
Ensuring Biologic Stability with Tailored and Cutting-Edge Lyophilization Solutions
April 14th 2025Explore how tailored lyophilization solutions, integrated with quality-by- design principles and advanced modeling, help optimize stability, reduce costs, and enhance global accessibility for biopharmaceuticals.
Top 10 Cleanroom Problems That Can Be Prevented via Preventative Maintenance
April 14th 2025Cleanrooms require strict environmental control to maintain sterility, prevent contamination, and ensure seamless operations. Without a proactive preventative maintenance (PM) program, various issues can arise, leading to costly downtime, contamination risks, and operational inefficiencies. Below are ten common cleanroom problems that can be effectively mitigated through proper PM practices.